OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MOLNR.TL54

JMolner AS

PharmaceuticalsVerified

JMolner AS has a fully diluted share count of 1,686,001 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics have been provided for comparison. Without revenue, EBITDA, or net income data, it is not possible to assess JMolner AS's performance relative to industry medians or to evaluate its return on invested capital (ROIC) or operating margins. Segment and geographic exposure data are not disclosed in the available financial reports. The company does not provide a breakdown of revenue by product line or geographic region, making it difficult to assess concentration risk or diversification. Growth trajectory data is also unavailable. No revenue history or outlook figures are provided for the current or next fiscal year, preventing an assessment of JMolner AS's growth potential or market expansion plans. Risk factors include the inability to assess liquidity risk and the lack of disclosed dilution potential. The absence of balance-sheet data and going-concern language raises concerns about the company's financial stability and operational continuity. No recent filings or transcripts are available to provide insight into management's strategic direction or operational updates.

30-day price · MOLNR.TL+0.40 (+1.7%)
Low$20.00High$24.20Close$23.60As of19 May, 00:00 UTC
Profile
CompanyJMolner AS
TickerMOLNR.TL
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. JMolner AS is a pharmaceutical company engaged in the development and commercialization of innovative drug therapies, primarily targeting oncology and rare diseases.

Classification. JMolner AS is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

JMolner AS has a fully diluted share count of 1,686,001 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics have been provided for comparison. Without revenue, EBITDA, or net income data, it is not possible to assess JMolner AS's performance relative to industry medians or to evaluate its return on invested capital (ROIC) or operating margins. Segment and geographic exposure data are not disclosed in the available financial reports. The company does not provide a breakdown of revenue by product line or geographic region, making it difficult to assess concentration risk or diversification. Growth trajectory data is also unavailable. No revenue history or outlook figures are provided for the current or next fiscal year, preventing an assessment of JMolner AS's growth potential or market expansion plans. Risk factors include the inability to assess liquidity risk and the lack of disclosed dilution potential. The absence of balance-sheet data and going-concern language raises concerns about the company's financial stability and operational continuity. No recent filings or transcripts are available to provide insight into management's strategic direction or operational updates.
Key takeaways
  • JMolner AS has no dilution risk from stock options or convertible securities, as basic and diluted shares are equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • No profitability metrics are available to compare JMolner AS's performance against industry benchmarks.
  • Revenue concentration and geographic exposure are not disclosed, limiting visibility into diversification and risk.
  • Growth trajectory and future revenue expectations are unknown due to the absence of historical and forward-looking data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$505.3k-$307.1k-$327.8k
FY-3$191.7k-$584.3k-$620.1k
FY-2$617.6k-$946.9k-$1.1M-$2.8M
FY-1$2.3M-$1.9M-$2.4M-$3.1M
FY0$1.1M$294.6k$127.9k-$670.8k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$425.8k-$325.2k$242.8k
FY-3$1.7M$261.6k$722.8k
FY-2$3.1M$263.2k$92.5k
FY-1$4.5M$924.8k
FY0$5.4M$2.1M
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2-$934.5k-$1.7M-$2.8M
FY-1-$1.9M-$749.6k-$3.1M
FY0-$1.5M-$1.1M-$670.8k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricMOLNR.TLActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:36 UTC#bc397b56
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 15:11 UTCJob: fa55dc43